• GSK posted a press release on ViiV Healthcare HIV data slated for AIDS 2026.
• Highlights include phase IIIb VOGUE head-to-head results comparing Dovato with Gilead’s Biktarvy in treatment-naïve adults.
• Update also flags new real-world OPERA findings for Cabenuva, GSK’s long-acting injectable HIV regimen.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202607210400BIZWIRE_USPR_____20260721_BW822679) on July 21, 2026, and is solely responsible for the information contained therein.